Correction to: Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
出版信息
Circulation. 2019 Jul 23;140(4):e171. doi: 10.1161/CIR.0000000000000712. Epub 2019 Jul 22.
Abstract
摘要
相似文献
1
Correction to: Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.对《阿利西尤单抗对急性冠脉综合征后死亡率的影响：ODYSSEY OUTCOMES随机临床试验分析》的更正
Circulation. 2019 Jul 23;140(4):e171. doi: 10.1161/CIR.0000000000000712. Epub 2019 Jul 22.
2
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.在伴有或不伴有糖尿病的急性冠脉综合征患者中，阿利西尤单抗对心血管和代谢结局的影响：ODYSSEY OUTCOMES 随机对照试验的预先指定分析。
Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Epub 2019 Jul 1.
3
Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial.在ODYSSEY OUTCOMES试验中，阿利西尤单抗可减少住院总次数，并增加存活且未住院的天数。
Circ Cardiovasc Qual Outcomes. 2019 Nov;12(11):e005858. doi: 10.1161/CIRCOUTCOMES.119.005858. Epub 2019 Nov 11.
4
Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndromes and hypercholesterolemia not adequately controlled with statins: ODYSSEY J-IVUS rationale and design.阿利西尤单抗对日本急性冠状动脉综合征和他汀类药物治疗控制不佳的高胆固醇血症患者冠状动脉粥样硬化体积的影响：ODYSSEY J-IVUS研究原理与设计。
J Cardiol. 2018 Jun;71(6):583-589. doi: 10.1016/j.jjcc.2017.11.013. Epub 2018 Mar 30.
5
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial.依洛尤单抗治疗多血管疾病及近期急性冠状动脉综合征患者：ODYSSEY OUTCOMES 试验。
J Am Coll Cardiol. 2019 Sep 3;74(9):1167-1176. doi: 10.1016/j.jacc.2019.03.013. Epub 2019 Mar 18.
6
Effect of Alirocumab on Mortality After Acute Coronary Syndromes.依洛尤单抗对急性冠脉综合征患者死亡率的影响。
Circulation. 2019 Jul 9;140(2):103-112. doi: 10.1161/CIRCULATIONAHA.118.038840. Epub 2019 May 23.
7
Cost-Effectiveness of Alirocumab: A Just-in-Time Analysis Based on the ODYSSEY Outcomes Trial.依洛尤单抗的成本效益：基于 ODYSSEY 结果试验的及时分析。
Ann Intern Med. 2019 Feb 19;170(4):221-229. doi: 10.7326/M18-1776. Epub 2019 Jan 1.
8
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.依洛尤单抗对急性冠状动脉综合征后脂蛋白(a)和心血管风险的影响。
J Am Coll Cardiol. 2020 Jan 21;75(2):133-144. doi: 10.1016/j.jacc.2019.10.057.
9
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.依洛尤单抗，一种针对前蛋白转化酶枯草溶菌素 9（PCSK9）的单克隆抗体，对急性冠脉综合征后长期心血管结局的影响：ODYSSEY 结局试验的原理和设计。
Am Heart J. 2014 Nov;168(5):682-9. doi: 10.1016/j.ahj.2014.07.028. Epub 2014 Aug 7.
10
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial.依洛尤单抗降低全因非致死性心血管事件和致死性事件：ODYSSEY OUTCOMES 试验。
J Am Coll Cardiol. 2019 Feb 5;73(4):387-396. doi: 10.1016/j.jacc.2018.10.039. Epub 2018 Nov 11.
引用本文的文献
1
Reduction of Cardiovascular Risk Using Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Acute Coronary Syndrome: A Systematic Review.在急性冠状动脉综合征患者中使用前蛋白转化酶枯草杆菌蛋白酶/kexin 9型抑制剂降低心血管风险：一项系统评价。
Cureus. 2023 Feb 5;15(2):e34648. doi: 10.7759/cureus.34648. eCollection 2023 Feb.
2
What Lessons Have We Learned and What Remains to be Clarified for PCSK9 Inhibitors? A Review of FOURIER and ODYSSEY Outcomes Trials.我们从PCSK9抑制剂中学到了哪些经验教训，还有哪些有待澄清？FOURIER和ODYSSEY结局试验综述
Cardiol Ther. 2020 Jun;9(1):59-73. doi: 10.1007/s40119-020-00163-w. Epub 2020 Feb 5.
Zotero 插件